发明名称 |
Oral dosing formulations of dideoxy purine nucleosides |
摘要 |
Improved oral dosage formulations for acid-labile dideoxy purine nucleoside derivatives such as ddA, ddI, and ddG, have been developed by incorporating selected water-insoluble buffering systems in the formulation. These novel formulations provide reduced mass dosage units in the form of convenient, palatable chewable/dispersible tablets or a dry powder sachet. The reduced mass requirement, necessary to allow tablets of reasonable size, was achieved in part by an unexpected 20 to 25% increase in drug bioavailability resulting from use of the selected buffering systems comprised of an insoluble magnesium antacid agent and either dihydroxyaluminum sodium carbonate or calcium carbonate.
|
申请公布号 |
US5880106(A) |
申请公布日期 |
1999.03.09 |
申请号 |
US19970942660 |
申请日期 |
1997.10.02 |
申请人 |
BRISTOL-MYERS SQUIBB COMPANY |
发明人 |
ULLAH, ISMAT;AGHARKAR, SHREERAM NARAHARI;WILEY, GARY JAMES |
分类号 |
A61K9/14;A61K;A61K9/00;A61K9/20;A61K31/495;A61K31/52;A61K31/70;A61K31/7076;A61K33/08;A61K33/10;A61K33/12;A61K33/42;A61K47/00;A61K47/02;A61K47/12;A61K47/32;A61K47/38;A61P31/12;(IPC1-7):A61K31/70 |
主分类号 |
A61K9/14 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|